NCT03995888View on ClinicalTrials.gov

Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 11, 2019

Primary Completion Date

April 16, 2020

Study Completion Date

April 16, 2020

Conditions
Prostate Cancer
Interventions
DRUG

rhPSMA-7.3 (18F) Injection

Radioligand for PET CT scanning

Trial Locations (1)

FI-20520

Clinical Research Services Turku - CRST Oy, Turku

Sponsors
All Listed Sponsors
lead

Blue Earth Diagnostics

INDUSTRY

NCT03995888 - Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer | Biotech Hunter | Biotech Hunter